Kyverna's miv-cel meets all endpoints in KYSA-8 SPS trial; median T25FW improvement 46% (p=0.0003)

Kyverna Therapeutics, Inc.

Single-dose miv-cel achieved statistically significant improvements across all primary and secondary endpoints at Week 16.
81% of patients achieved ≥20% improvement in T25FW; 67% of walking-aid users no longer needed assistance.
All 26 patients discontinued chronic immunotherapies through last follow-up; no high-grade CRS or ICANS observed.
Company plans to submit BLA for miv-cel in SPS; data also support potential in myasthenia gravis.
Natural history study of 153 SPS patients showed minimal improvement with current treatments, underscoring unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.